ALTITUDE (2012) — Trial Summary

ALTITUDE (2012): The ALTITUDE trial evaluated whether direct renin inhibition with aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and CKD already on RAAS blockade.

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.